STOCK TITAN

[6-K] Nomura Holdings, Inc Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Serina Therapeutics, Inc. (NYSE American: SER) filed a Form 8-K on 29-Jul-2025 under Item 7.01 (Regulation FD). The filing furnishes—rather than files—a press release and an investor presentation (Exhibits 99.2 and 99.1) that spotlight the advancement of SER-270 (POZ-VMAT2i), a proprietary POZ-conjugated VMAT2 inhibitor in development for tardive dyskinesia. CEO Steve Ledger will discuss the program during the BTIG Virtual Biotechnology Conference on the same day using the accompanying presentation materials. No financial results, clinical data, guidance, or other material transactions are disclosed, and the company expressly states the furnished information will not be incorporated into future Securities Act filings unless specifically referenced. No other Items were reported.

Serina Therapeutics, Inc. (NYSE American: SER) ha presentato un Modulo 8-K il 29 luglio 2025 ai sensi dell'Articolo 7.01 (Regolamento FD). La comunicazione fornisce — anziché depositare — un comunicato stampa e una presentazione per investitori (Allegati 99.2 e 99.1) che evidenziano i progressi di SER-270 (POZ-VMAT2i), un inibitore VMAT2 coniugato POZ proprietario in fase di sviluppo per la discinesia tardiva. Il CEO Steve Ledger discuterà il programma durante la Conferenza Virtuale BTIG Biotechnology lo stesso giorno, utilizzando i materiali della presentazione allegata. Non vengono divulgati risultati finanziari, dati clinici, indicazioni o altre transazioni rilevanti, e la società dichiara espressamente che le informazioni fornite non saranno incorporate in future comunicazioni ai sensi del Securities Act, salvo specifico riferimento. Non sono stati segnalati altri punti.

Serina Therapeutics, Inc. (NYSE American: SER) presentó un Formulario 8-K el 29 de julio de 2025 bajo el Punto 7.01 (Regulación FD). El informe proporciona — en lugar de presentar — un comunicado de prensa y una presentación para inversores (Exhibiciones 99.2 y 99.1) que destacan el avance de SER-270 (POZ-VMAT2i), un inhibidor VMAT2 conjugado con POZ patentado en desarrollo para la discinesia tardía. El CEO Steve Ledger hablará sobre el programa durante la Conferencia Virtual de Biotecnología BTIG ese mismo día, utilizando los materiales de presentación adjuntos. No se divulgan resultados financieros, datos clínicos, orientaciones ni otras transacciones relevantes, y la compañía declara expresamente que la información proporcionada no se incorporará en futuras presentaciones bajo la Ley de Valores a menos que se haga referencia específica. No se reportaron otros puntos.

Serina Therapeutics, Inc. (NYSE American: SER)는 2025년 7월 29일 항목 7.01(규정 FD)에 따라 Form 8-K를 제출했습니다. 이번 제출은 파일 제출이 아닌 보도자료와 투자자 프레젠테이션(첨부문서 99.2 및 99.1)을 제공하며, 지연성 운동장애 치료를 위한 독점 POZ-결합 VMAT2 억제제인 SER-270 (POZ-VMAT2i)의 개발 진전을 강조합니다. CEO Steve Ledger는 같은 날 BTIG 가상 바이오테크 회의에서 첨부된 발표 자료를 활용해 프로그램에 대해 논의할 예정입니다. 재무 결과, 임상 데이터, 가이드라인 또는 기타 주요 거래는 공개되지 않았으며, 회사는 제공된 정보가 특별히 참조되지 않는 한 향후 증권법 관련 제출물에 포함되지 않을 것임을 명확히 밝혔습니다. 다른 항목은 보고되지 않았습니다.

Serina Therapeutics, Inc. (NYSE American : SER) a déposé un formulaire 8-K le 29 juillet 2025 en vertu de l'article 7.01 (Règlement FD). Le dépôt fournit — plutôt que de déposer — un communiqué de presse et une présentation aux investisseurs (Pièces 99.2 et 99.1) mettant en lumière les progrès de SER-270 (POZ-VMAT2i), un inhibiteur VMAT2 conjugué POZ propriétaire en développement pour la dyskinésie tardive. Le PDG Steve Ledger présentera le programme lors de la conférence virtuelle BTIG Biotechnology le même jour, en utilisant les supports de présentation fournis. Aucun résultat financier, donnée clinique, orientation ou autre transaction importante n’est divulgué, et la société précise expressément que les informations fournies ne seront pas intégrées dans de futures déclarations au titre du Securities Act, sauf mention expresse. Aucun autre point n’a été rapporté.

Serina Therapeutics, Inc. (NYSE American: SER) reichte am 29. Juli 2025 ein Formular 8-K gemäß Punkt 7.01 (Regulation FD) ein. Die Einreichung stellt – statt einzureichen – eine Pressemitteilung und eine Investorenpräsentation (Anlagen 99.2 und 99.1) bereit, die den Fortschritt von SER-270 (POZ-VMAT2i) hervorheben, einem proprietären POZ-konjugierten VMAT2-Inhibitor in Entwicklung für tardive Dyskinesie. CEO Steve Ledger wird das Programm am selben Tag während der BTIG Virtual Biotechnology Conference anhand der beiliegenden Präsentationsmaterialien erläutern. Es werden keine Finanzergebnisse, klinischen Daten, Prognosen oder sonstige wesentliche Transaktionen offengelegt, und das Unternehmen erklärt ausdrücklich, dass die bereitgestellten Informationen nicht in zukünftige Einreichungen gemäß dem Securities Act aufgenommen werden, sofern nicht ausdrücklich darauf Bezug genommen wird. Weitere Punkte wurden nicht gemeldet.

Positive
  • Pipeline visibility: Management spotlights SER-270, reinforcing pipeline momentum ahead of investor meetings.
Negative
  • No new clinical or financial data: Filing offers no efficacy, safety, or revenue guidance, limiting immediate valuation impact.
  • Information only furnished: Data are not deemed filed, suggesting limited materiality.

Insights

TL;DR: Neutral 8-K furnishes pipeline update; informative but lacks data or financial impact.

The company’s decision to highlight SER-270 via Regulation FD suggests it wants to raise visibility ahead of a conference rather than announce inflection-point results. Investors learn that a VMAT2 inhibitor has progressed internally, but without efficacy, safety, or regulatory milestones the disclosure is not immediately price-moving. The lack of financial metrics or guidance further limits impact. Nevertheless, the mention of proprietary POZ chemistry may remind the market of Serina’s platform potential and help management gauge investor interest.

Serina Therapeutics, Inc. (NYSE American: SER) ha presentato un Modulo 8-K il 29 luglio 2025 ai sensi dell'Articolo 7.01 (Regolamento FD). La comunicazione fornisce — anziché depositare — un comunicato stampa e una presentazione per investitori (Allegati 99.2 e 99.1) che evidenziano i progressi di SER-270 (POZ-VMAT2i), un inibitore VMAT2 coniugato POZ proprietario in fase di sviluppo per la discinesia tardiva. Il CEO Steve Ledger discuterà il programma durante la Conferenza Virtuale BTIG Biotechnology lo stesso giorno, utilizzando i materiali della presentazione allegata. Non vengono divulgati risultati finanziari, dati clinici, indicazioni o altre transazioni rilevanti, e la società dichiara espressamente che le informazioni fornite non saranno incorporate in future comunicazioni ai sensi del Securities Act, salvo specifico riferimento. Non sono stati segnalati altri punti.

Serina Therapeutics, Inc. (NYSE American: SER) presentó un Formulario 8-K el 29 de julio de 2025 bajo el Punto 7.01 (Regulación FD). El informe proporciona — en lugar de presentar — un comunicado de prensa y una presentación para inversores (Exhibiciones 99.2 y 99.1) que destacan el avance de SER-270 (POZ-VMAT2i), un inhibidor VMAT2 conjugado con POZ patentado en desarrollo para la discinesia tardía. El CEO Steve Ledger hablará sobre el programa durante la Conferencia Virtual de Biotecnología BTIG ese mismo día, utilizando los materiales de presentación adjuntos. No se divulgan resultados financieros, datos clínicos, orientaciones ni otras transacciones relevantes, y la compañía declara expresamente que la información proporcionada no se incorporará en futuras presentaciones bajo la Ley de Valores a menos que se haga referencia específica. No se reportaron otros puntos.

Serina Therapeutics, Inc. (NYSE American: SER)는 2025년 7월 29일 항목 7.01(규정 FD)에 따라 Form 8-K를 제출했습니다. 이번 제출은 파일 제출이 아닌 보도자료와 투자자 프레젠테이션(첨부문서 99.2 및 99.1)을 제공하며, 지연성 운동장애 치료를 위한 독점 POZ-결합 VMAT2 억제제인 SER-270 (POZ-VMAT2i)의 개발 진전을 강조합니다. CEO Steve Ledger는 같은 날 BTIG 가상 바이오테크 회의에서 첨부된 발표 자료를 활용해 프로그램에 대해 논의할 예정입니다. 재무 결과, 임상 데이터, 가이드라인 또는 기타 주요 거래는 공개되지 않았으며, 회사는 제공된 정보가 특별히 참조되지 않는 한 향후 증권법 관련 제출물에 포함되지 않을 것임을 명확히 밝혔습니다. 다른 항목은 보고되지 않았습니다.

Serina Therapeutics, Inc. (NYSE American : SER) a déposé un formulaire 8-K le 29 juillet 2025 en vertu de l'article 7.01 (Règlement FD). Le dépôt fournit — plutôt que de déposer — un communiqué de presse et une présentation aux investisseurs (Pièces 99.2 et 99.1) mettant en lumière les progrès de SER-270 (POZ-VMAT2i), un inhibiteur VMAT2 conjugué POZ propriétaire en développement pour la dyskinésie tardive. Le PDG Steve Ledger présentera le programme lors de la conférence virtuelle BTIG Biotechnology le même jour, en utilisant les supports de présentation fournis. Aucun résultat financier, donnée clinique, orientation ou autre transaction importante n’est divulgué, et la société précise expressément que les informations fournies ne seront pas intégrées dans de futures déclarations au titre du Securities Act, sauf mention expresse. Aucun autre point n’a été rapporté.

Serina Therapeutics, Inc. (NYSE American: SER) reichte am 29. Juli 2025 ein Formular 8-K gemäß Punkt 7.01 (Regulation FD) ein. Die Einreichung stellt – statt einzureichen – eine Pressemitteilung und eine Investorenpräsentation (Anlagen 99.2 und 99.1) bereit, die den Fortschritt von SER-270 (POZ-VMAT2i) hervorheben, einem proprietären POZ-konjugierten VMAT2-Inhibitor in Entwicklung für tardive Dyskinesie. CEO Steve Ledger wird das Programm am selben Tag während der BTIG Virtual Biotechnology Conference anhand der beiliegenden Präsentationsmaterialien erläutern. Es werden keine Finanzergebnisse, klinischen Daten, Prognosen oder sonstige wesentliche Transaktionen offengelegt, und das Unternehmen erklärt ausdrücklich, dass die bereitgestellten Informationen nicht in zukünftige Einreichungen gemäß dem Securities Act aufgenommen werden, sofern nicht ausdrücklich darauf Bezug genommen wird. Weitere Punkte wurden nicht gemeldet.

Table of Contents
 
 

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

Commission File Number: 1-15270

For the month of July 2025

NOMURA HOLDINGS, INC.

(Translation of registrant’s name into English)

13-1, Nihonbashi 1-chome

Chuo-ku, Tokyo 103-8645

Japan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  X    Form 40-F    

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):    

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):    

 

 
 


Table of Contents

Information furnished on this form:

EXHIBIT

 

Exhibit Number
1.    Financial Summary – Three months ended June 30, 2025.

The registrant hereby incorporates Exhibit 1 to this report on Form 6-K by reference (i) in the prospectus that is part of the Registration Statement on Form F-3 (Registration No. 333-283915) of the registrant, filed with the SEC on December 19, 2024 and (ii) in the prospectus that is part of the Registration Statement on Form F-3 (Registration No. 333-273353) of the registrant and of Nomura America Finance, LLC, filed with the SEC on July 20, 2023.


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   NOMURA HOLDINGS, INC.
Date: July 29, 2025    By:   

/s/ Yoshifumi Kishida

      Yoshifumi Kishida
      Senior Managing Director


Table of Contents

Financial Summary For the Three Months Ended June 30, 2025 (U.S. GAAP)

 

Date:    July 29, 2025
Company name (code number):    Nomura Holdings, Inc. (8604)
Stock exchange listings:   

(In Japan) Tokyo, Nagoya

(Overseas) New York, Singapore

Representative:   

Kentaro Okuda

President and Group CEO, Nomura Holdings, Inc.

For inquiries:   

Akihiro Koseki

Managing Director, Head of Investor Relations, Nomura Holdings, Inc.

Tel: (Country Code 81) 3-5255-1000

URL: https://www.nomura.com

1. Consolidated Operating Results

(1) Operating Results

 

     (Rounded to nearest million)  
     (Millions of yen, except per share data)  
     For the three months ended June 30  
     2024     2025  
           % Change from
June 30, 2023
          % Change from
June 30, 2024
 

Total revenue

     1,217,885       36.3         1,156,588       (5.0 %) 

Net revenue

     454,442       30.2     523,315       15.2

Income before income taxes

     102,931       122.3     160,282       55.7

Net income attributable to Nomura Holdings, Inc. (“NHI”) shareholders

     68,938       195.5     104,565       51.7

Comprehensive income

     189,295            49.9     61,629             (67.4 %) 

Basic-Net income attributable to NHI shareholders per share (Yen)

     23.33         35.19    

Diluted-Net income attributable to NHI shareholders per share (Yen)

     22.36         34.04    

Return on shareholders’ equity - annualized

     8.1       12.0  

Note: Return on shareholders’ equity is a ratio of Net income attributable to NHI shareholders to Total NHI shareholders’ equity.

(2) Financial Position

 

     (Millions of yen, except per share data)  
     At March 31     At June 30  
   2025     2025  

Total assets

        56,802,170            58,101,087  

Total equity

     3,580,999       3,588,951  

Total NHI shareholders’ equity

     3,470,879       3,476,014  

Total NHI shareholders’ equity as a percentage of total assets

     6.1     6.0

Total NHI shareholders’ equity per share (Yen)

     1,174.10       1,177.31  


Table of Contents

2. Cash Dividends

 

           (Yen amounts)  
     For the year ended March 31  
   2025     2026     2026 (Plan)  

Dividends per share

      

Dividends record dates

      

At June 30

           —              —         —   

At September 30

     23.00              —           Unconfirmed  

At December 31

     —              —         —    

At March 31

     34.00             —         Unconfirmed  

For the year

     57.00             —         Unconfirmed  

Note: Fiscal year 2026 Q2 and Q4 dividends are not presented per reasons stated in “3. Earnings forecasts for the year ending March 31, 2026”.

3. Earnings Forecasts for the year ending March 31, 2026

Nomura provides investment, financing and related services in the capital markets on a global basis. In the global capital markets there exist uncertainties due to, but not limited to, economic and market conditions. Nomura, therefore, does not present earnings forecasts.

Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Adoption of the simplified and particular accounting treatments: None

(3) Changes in accounting policies

  a)  Changes in accounting policies due to amendments to the accounting standards : Yes

  b)  Changes in accounting policies due to other than a) : None

Note) Please refer to P.10 “2. Quarterly Consolidated Financial Statements (4) Changes in Accounting Policies” for further details.

(4) Number of shares issued (common stock)

 

     At March 31      At June 30  
   2025      2025  

Number of shares outstanding (including treasury stock)

     3,163,562,601        3,163,562,601   

Number of treasury stock

     207,351,636        211,064,772  
     For the three months ended June 30  
   2024      2025  

Average number of shares outstanding (year-to-date)

     2,954,604,002        2,971,653,091   

*Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

*Proper use of earnings forecasts, and other special matters

We voluntarily have engaged our independent auditor to conduct a review of the quarterly consolidated financial statements. We plan to release the quarterly financial statements with the accompanying review report on August 7, 2025.


Table of Contents

Table of Contents for the Accompanying Materials

 

1. Qualitative Information of the Quarterly Consolidated Results

    P. 2  

(1) Consolidated Operating Results

    P. 2  

(2) Consolidated Financial Position

    P. 4  

(3) Consolidated Earnings Forecasts

    P. 4  

2. Quarterly Consolidated Financial Statements

    P. 5  

(1) Consolidated Balance Sheets

    P. 6  

(2) Consolidated Statements of Income

    P. 8  

(3) Consolidated Statements of Comprehensive Income

    P. 9  

(4) Changes in Accounting Policies

    P. 10  

(5) Segment Information – Operating Segment

    P. 10  

(6) Significant Changes in Equity

    P. 12  

(7) Note with respect to the Assumption as a Going Concern

    P. 13  

(8) Note with respect to Consolidated Statements of Cash Flows

    P. 13  

3. Supplementary Information

    P. 14  

(1) Consolidated Statements of Income – Quarterly Comparatives

    P. 14  

(2) Business Segment Information – Quarterly Comparatives

    P. 15  

(3) Other

    P. 16  

 

– 1 –


Table of Contents
1.

Qualitative Information of the Quarterly Consolidated Results

 

(1)

Consolidated Operating Results

 U.S. GAAP

 

     Billions of yen     % Change  
   For the three months ended     (B-A)/(A)  
   June 30,
2024 (A)
    June 30,
2025 (B)
 

Net revenue

        454.4          523.3            15.2  

Non-interest expenses

     351.5       363.0       3.3  
  

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

     102.9       160.3       55.7  

Income tax expense

     31.5       52.8       67.7  
  

 

 

   

 

 

   

 

 

 

Net income (loss)

     71.4       107.5       50.5  
  

 

 

   

 

 

   

 

 

 

Less: Net income (loss) attributable to noncontrolling interests

     2.5       2.9       16.6  
  

 

 

   

 

 

   

 

 

 

Net income (loss) attributable to NHI shareholders

     68.9       104.6       51.7  
  

 

 

   

 

 

   

 

 

 

Return on shareholders’ equity - annualized

     8.1     12.0     —   
  

 

 

   

 

 

   

 

 

 

Note: Return on shareholders’ equity is a ratio of Net income (loss) attributable to NHI shareholders to Total NHI shareholders’ equity.

Nomura Holdings, Inc. and its consolidated entities (collectively, “Nomura”) reported net revenue of 523.3 billion yen for the three months ended June 30, 2025, an increase of 15.2% from the same period in the prior year. Non-interest expenses increased by 3.3% from the same period in the prior year to 363.0 billion yen. Income before income taxes was 160.3 billion yen and net income attributable to NHI shareholders was 104.6 billion yen for the three months ended June 30, 2025.

 Segment Information

 

     Billions of yen     % Change  
   For the three months ended     (B-A)/(A)  
   June 30,
2024 (A)
    June 30,
2025 (B)
 

Net revenue

     453.2         523.4       15.5  

Non-interest expenses

        351.5          363.0         3.3  
  

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

     101.7       160.4           57.7  
  

 

 

   

 

 

   

 

 

 

In the above segment information totals, which exclude a part of unrealized gain (loss) on investments in equity securities held for operating purposes, net revenue for the three months ended June 30, 2025 was 523.4 billion yen, an increase of 15.5% from the same period in the prior year. Non-interest expenses increased by 3.3% from the same period in the prior year to 363.0 billion yen. Income before income taxes increased by 57.7% to 160.4 billion yen for the three months ended June 30, 2025. Please refer to page 10 for further details of the differences between U.S. GAAP and business segment amounts.

 

– 2 –


Table of Contents

<Business Segment Results>

On April 1, 2025, the Banking Division was newly established. As a result, the prior period amounts have been reclassified to conform to the current year presentation.

 Operating Results of Wealth Management

 

     Billions of yen     % Change  
   For the three months ended     (B-A)/(A)  
   June 30,
2024 (A)
     June 30,
2025 (B)
 

Net revenue

          109.7        105.8              (3.6

Non-interest expenses

     68.5             67.0         (2.2
  

 

 

    

 

 

   

 

 

 

Income (loss) before income taxes

     41.2        38.8       (5.9
  

 

 

    

 

 

   

 

 

 

Net revenue decreased by 3.6% from the same period in the prior year to 105.8 billion yen. Non-interest expenses decreased by 2.2% to 67.0 billion yen. As a result, income before income taxes decreased by 5.9% to 38.8 billion yen.

 Operating Results of Investment Management

 

     Billions of yen     % Change  
   For the three months ended     (B-A)/(A)  
   June 30,
2024 (A)
    June 30,
2025 (B)
 

Net revenue

     47.7       50.6       6.1  

Non-interest expenses

     24.5           29.0              18.6   
  

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

          23.2        21.5         (7.1
  

 

 

   

 

 

   

 

 

 

Net revenue increased by 6.1% from the same period in the prior year to 50.6 billion yen. Non-interest expenses increased by 18.6% to 29.0 billion yen. As a result, income before income taxes decreased by 7.1% to 21.5 billion yen. Assets under management were 94.3 trillion yen as of June 30, 2025.

 Operating Results of Wholesale

 

     Billions of yen     % Change  
   For the three months ended     (B-A)/(A)  
   June 30,
2024 (A)
    June 30,
2025 (B)
 

Net revenue

        244.8            261.1         6.6  

Non-interest expenses

     223.7       219.2              (2.0
  

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

     21.1       41.9       98.4  
  

 

 

   

 

 

   

 

 

 

Net revenue increased by 6.6% from the same period in the prior year to 261.1 billion yen. Non-interest expenses decreased by 2.0% to 219.2 billion yen. As a result, income before income taxes increased by 98.4% to 41.9 billion yen.

 

– 3 –


Table of Contents

 Operating Results of Banking

 

     Billions of yen      % Change  
   For the three months ended      (B-A)/(A)  
   June 30,
2024 (A)
     June 30,
2025 (B)
 

Net revenue

         11.2            12.8        14.4  

Non-interest expenses

     7.2        9.2        28.2  
  

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

     4.0        3.6               (10.4
  

 

 

    

 

 

    

 

 

 

Net revenue increased by 14.4% from the same period in the prior year to 12.8 billion yen. Non-interest expenses increased by 28.2% to 9.2 billion yen. As a result, income before income taxes decreased by 10.4% to 3.6 billion yen.

 Other Operating Results

 

     Billions of yen      % Change  
   For the three months ended      (B-A)/(A)  
   June 30,
2024 (A)
     June 30,
2025 (B)
 

Net revenue

         39.7            93.2        134.4  

Non-interest expenses

     27.6        38.6        39.8  
  

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

     12.2        54.6               349.1   
  

 

 

    

 

 

    

 

 

 

Net revenue was 93.2 billion yen, primarily due to profits related to the sale of land and buildings located in Takanawa 2-chome, Minato-ku, Tokyo, recorded in April 2025. Income before income taxes was 54.6 billion yen.

 

(2)

Consolidated Financial Position

Total assets as of June 30, 2025 were 58,101.1 billion yen, an increase of 1,298.9 billion yen compared to March 31, 2025, mainly due to the increase in Trading assets. Total liabilities as of June 30, 2025 were 54,512.1 billion yen, an increase of 1,291.0 billion yen compared to March 31, 2025, mainly due to the increase in Trading liabilities. Total equity as of June 30, 2025 was 3,589.0 billion yen, an increase of 8.0 billion yen compared to March 31, 2025.

 

(3)

Consolidated Earnings Forecasts

Nomura provides investment, financing and related services in the capital markets on a global basis. In the global capital markets there exist uncertainties due to, but not limited to, economic and market conditions. Nomura, therefore, does not present earnings and dividend forecasts.

 

– 4 –


Table of Contents
2.

Quarterly Consolidated Financial Statements

Nomura’s quarterly consolidated financial statements, which comprise the consolidated balance sheet, consolidated statement of income, consolidated statement of comprehensive income and notes, have been prepared in accordance with Article 5, Paragraph 4 of the Tokyo Stock Exchange Inc. and Nagoya Stock Exchange Inc.’s Standards for the Preparation of Quarterly Financial Statements (the Standards) and accounting principles generally accepted in the United States, applying the provisions for reduced disclosures as set forth in Article 5, Paragraph 5 of the Standards.

The quarterly consolidated financial statements herein have been prepared in accordance with Nomura’s accounting policies which are disclosed in the notes to the consolidated financial statements of Nomura Holdings, Inc.’s Annual Securities Report (the annual report filed in Japan on June 23, 2025) and Form 20-F (the annual report filed with the U.S. Securities and Exchange Commission on June 23, 2025) for the year ended March 31, 2025, with the exception of matters described in (4) Changes in Accounting Policies.

 

– 5 –


Table of Contents

(1) Consolidated Balance Sheets

 

     Millions of yen  
     March 31,
2025
    June 30,
2025
    Increase/
(Decrease)
 
ASSETS       

Cash and cash deposits:

      

Cash and cash equivalents

     4,424,462       4,983,234       558,772  

Time deposits

     642,388       569,880       (72,508

Deposits with stock exchanges and other segregated cash

     447,846       494,678       46,832  
  

 

 

   

 

 

   

 

 

 

Total cash and cash deposits

     5,514,696       6,047,792       533,096  
  

 

 

   

 

 

   

 

 

 

Loans and receivables:

      

Loans receivable

     6,025,008       6,146,160       121,152  

Receivables from customers

     410,722       379,901       (30,821

Receivables from other than customers

     1,030,023       976,170       (53,853

Allowance for credit losses

     (16,920     (16,702     218  
  

 

 

   

 

 

   

 

 

 

Total loans and receivables

     7,448,833       7,485,529       36,696  
  

 

 

   

 

 

   

 

 

 

Collateralized agreements:

      

Securities purchased under agreements to resell

     14,004,757       12,964,351       (1,040,406

Securities borrowed

     4,658,828       4,346,746       (312,082
  

 

 

   

 

 

   

 

 

 

Total collateralized agreements

     18,663,585       17,311,097       (1,352,488
  

 

 

   

 

 

   

 

 

 

Trading assets and private equity and debt investments:

      

Trading assets*

     22,372,339       24,233,906       1,861,567  

Private equity and debt investments*

     151,710       153,785       2,075  
  

 

 

   

 

 

   

 

 

 

Total trading assets and private equity and debt investments

     22,524,049       24,387,691       1,863,642  
  

 

 

   

 

 

   

 

 

 

Other assets:

      

Office buildings, land, equipment and facilities

(net of accumulated depreciation and amortization of

¥ 546,117 million as of March 31, 2025 and

¥ 534,830 million as of June 30, 2025)

     436,454       414,971       (21,483

Non-trading debt securities*

     485,290       558,924       73,634  

Investments in equity securities*

     98,401       96,963       (1,438

Investments in and advances to affiliated companies*

     506,389       508,806       2,417  

Other

     1,124,473       1,289,314       164,841  
  

 

 

   

 

 

   

 

 

 

Total other assets

     2,651,007       2,868,978       217,971  
  

 

 

   

 

 

   

 

 

 

Total assets

     56,802,170       58,101,087       1,298,917  
  

 

 

   

 

 

   

 

 

 
 
* 

Including securities pledged as collateral

 

– 6 –


Table of Contents
             Millions of yen  
             March 31,
2025
    June 30,
2025
    Increase/
(Decrease)
 
LIABILITIES AND EQUITY       

Short-term borrowings

     1,117,292       1,322,134       204,842  

Payables and deposits:

      

Payables to customers

     1,377,222       1,545,461       168,239  

Payables to other than customers

     2,766,112       2,501,203       (264,909

Deposits received at banks

     3,105,581       3,085,645       (19,936
      

 

 

   

 

 

   

 

 

 

Total payables and deposits

     7,248,915       7,132,309       (116,606
      

 

 

   

 

 

   

 

 

 

Collateralized financing:

      

Securities sold under agreements to repurchase

     16,287,758       15,378,015       (909,743

Securities loaned

     1,964,682       1,679,632       (285,050

Other secured borrowings

     393,420       341,410       (52,010
      

 

 

   

 

 

   

 

 

 

Total collateralized financing

     18,645,860       17,399,057       (1,246,803
      

 

 

   

 

 

   

 

 

 

Trading liabilities

     11,378,828       13,281,663       1,902,835  

Other liabilities

     1,456,598       1,448,150       (8,448

Long-term borrowings

     13,373,678       13,928,823       555,145  
      

 

 

   

 

 

   

 

 

 

Total liabilities

     53,221,171       54,512,136       1,290,965  
      

 

 

   

 

 

   

 

 

 

Equity

      

NHI shareholders’ equity:

      

Common stock

      

   Authorized

   -    6,000,000,000 shares       

 Issued

   -    3,163,562,601 shares as of March 31, 2025 and       
    3,163,562,601 shares as of June 30, 2025       

Outstanding

   -    2,956,210,965 shares as of March 31, 2025 and       
    2,952,497,829 shares as of June 30, 2025      594,493       594,493       —   

Additional paid-in capital

     704,877       670,541       (34,336

Retained earnings

     1,867,379       1,963,109       95,730  

Accumulated other comprehensive income (loss)

     447,808       401,525       (46,283
      

 

 

   

 

 

   

 

 

 

Total NHI shareholders’ equity before treasury stock

     3,614,557       3,629,668       15,111  

Common stock held in treasury, at cost -

      

         207,351,636 shares as of March 31, 2025 and

      

         211,064,772 shares as of June 30, 2025

     (143,678     (153,654     (9,976
      

 

 

   

 

 

   

 

 

 

Total NHI shareholders’ equity

     3,470,879       3,476,014       5,135  
      

 

 

   

 

 

   

 

 

 

Noncontrolling interests

     110,120       112,937       2,817  
      

 

 

   

 

 

   

 

 

 

Total equity

     3,580,999       3,588,951       7,952  
      

 

 

   

 

 

   

 

 

 

Total liabilities and equity

     56,802,170       58,101,087       1,298,917  
      

 

 

   

 

 

   

 

 

 

 

– 7 –


Table of Contents

(2) Consolidated Statements of Income

 

     Millions of yen     % Change  
   For the three months ended     (B-A)/(A)  
   June 30,
2024(A)
     June 30,
2025(B)
 

Revenue:

                                                   

Commissions

     102,750        100,606       (2.1

Fees from investment banking

     41,251        38,357       (7.0

Asset management and portfolio service fees

     90,333        92,855       2.8  

Net gain on trading

     131,994        142,239       7.8  

Gain on private equity and debt investments

     3,153        6,330       100.8  

Interest and dividends

     788,550        649,561       (17.6

Gain (loss) on investments in equity securities

     1,442        (377     —   

Other

     58,412        127,017       117.5  
  

 

 

    

 

 

   

 

 

 

Total revenue

     1,217,885        1,156,588       (5.0

Interest expense

     763,443        633,273       (17.1
  

 

 

    

 

 

   

 

 

 

Net revenue

     454,442        523,315       15.2  
  

 

 

    

 

 

   

 

 

 

Non-interest expenses:

       

Compensation and benefits

     184,510        186,310       1.0  

Commissions and floor brokerage

     43,629        44,778       2.6  

Information processing and communications

     55,769        57,164       2.5  

Occupancy and related depreciation

     17,635        15,965       (9.5

Business development expenses

     6,572        6,992       6.4  

Other

     43,396        51,824       19.4  
  

 

 

    

 

 

   

 

 

 

Total non-interest expenses

     351,511        363,033       3.3  
  

 

 

    

 

 

   

 

 

 

Income before income taxes

     102,931        160,282       55.7  

Income tax expense

     31,498        52,808       67.7  
  

 

 

    

 

 

   

 

 

 

Net income

     71,433        107,474       50.5  
  

 

 

    

 

 

   

 

 

 

Less: Net income attributable to noncontrolling interests

     2,495        2,909       16.6  
  

 

 

    

 

 

   

 

 

 

Net income attributable to NHI shareholders

     68,938        104,565       51.7  
  

 

 

    

 

 

   

 

 

 

Per share of common stock:

       
     Yen     % Change  

Basic-

       

Net income attributable to NHI shareholders per share

     23.33        35.19       50.8  
  

 

 

    

 

 

   

 

 

 

Diluted-

       

Net income attributable to NHI shareholders per share

     22.36        34.04       52.2  
  

 

 

    

 

 

   

 

 

 

 

– 8 –


Table of Contents

(3) Consolidated Statements of Comprehensive Income

 

     Millions of yen     % Change  
   For the three months ended     (B-A)/(A)  
   June 30,
2024(A)
    June 30,
2025(B)
 

Net income

         71,433          107,474            50.5  

Other comprehensive income (loss):

      

Cumulative translation adjustments:

      

Cumulative translation adjustments

     113,443       (40,858     —   

Deferred income taxes

     (1,608     1,258       —   
  

 

 

   

 

 

   

 

 

 

Total

     111,835       (39,600     —   
  

 

 

   

 

 

   

 

 

 

Defined benefit pension plans:

      

Pension liability adjustment

     (1,797     (4,197     —   

Deferred income taxes

     578       (3     —   
  

 

 

   

 

 

   

 

 

 

Total

     (1,219     (4,200     —   
  

 

 

   

 

 

   

 

 

 

Non-trading debt securities:

      

Net unrealized gain (loss) on non-trading debt securities

     (103     565       —   

Deferred income taxes

     32       (178     —   
  

 

 

   

 

 

   

 

 

 

Total

     (71     387       —   
  

 

 

   

 

 

   

 

 

 

Own credit adjustments:

      

Own credit adjustments

     9,856       (3,880     —   

Deferred income taxes

     (2,539     1,448       —   
  

 

 

   

 

 

   

 

 

 

Total

     7,317       (2,432     —   
  

 

 

   

 

 

   

 

 

 

Total other comprehensive income (loss)

     117,862       (45,845     —   
  

 

 

   

 

 

   

 

 

 

Comprehensive income

     189,295       61,629       (67.4

Less: Comprehensive income attributable to noncontrolling interests

     3,983       3,347       (16.0
  

 

 

   

 

 

   

 

 

 

Comprehensive income attributable to NHI shareholders

     185,312       58,282       (68.5
  

 

 

   

 

 

   

 

 

 

 

– 9 –


Table of Contents

(4) Changes in Accounting Policies

Intangibles—Goodwill and Other—Crypto Asset: Accounting for and Disclosure of Crypto Assets

In December 2023, the Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) No. 2023-08Intangibles—Goodwill and Other—Crypto Asset: Accounting for and Disclosure of Crypto Assets” which requires all in-scope crypto assets be subsequently measured at fair value at each reporting period through earnings. The ASU requires presentation of in-scope crypto assets separately from other intangible assets in the balance sheet and any changes from the remeasurement of in-scope crypto assets separately from changes in the carrying amounts of other intangible assets in the income statement. The ASU also introduces new disclosure requirements for in-scope crypto assets applicable to all entities. Nomura has applied this new accounting policy based on a modified retrospective approach from April 1, 2025. These accounting changes have not had a material impact on Nomura’s consolidated financial statements.

(5) Segment Information – Operating Segment

Nomura’s Chief Operating Decision Maker is the Executive Management Board (the “EMB”) which is the management function primarily responsible for assessing performance of and allocating resources to the business segments. The EMB reviews business segment results including Net revenue, Non-interest expenses, and Income before income taxes on a regular basis. The EMB uses these measures along with certain segment-specific Key Performance Indicators (KPIs) and budgets to evaluate segment performance and to make key operating decisions, including resource and capital allocations. Business segments’ information on total assets is not disclosed as EMB does not consider such information for its operating decisions and therefore, it is not reported.

 

– 10 –


Table of Contents

The following table shows business segment information and reconciliation items to the consolidated statements of income.

 

     Millions of yen     % Change  
   For the three months ended     (B-A)/(A)  
   June 30,
2024 (A)
     June 30,
2025 (B)
 

Net revenue

       

Business segment information:

       

Wealth Management

     109,716        105,796       (3.6

Investment Management

     47,670        50,574       6.1  

Wholesale

     244,846        261,072       6.6  

Banking

     11,232        12,845       14.4  
  

 

 

    

 

 

   

 

 

 

Subtotal

     413,464        430,287       4.1  

Other

     39,739        93,160       134.4  
  

 

 

    

 

 

   

 

 

 

Net revenue

     453,203        523,447       15.5  
  

 

 

    

 

 

   

 

 

 

Reconciliation items:

       

Unrealized gain (loss) on investments in equity securities held for operating purposes

     1,239        (132     —   
  

 

 

    

 

 

   

 

 

 

Net revenue

     454,442        523,315       15.2  
  

 

 

    

 

 

   

 

 

 

Non-interest expenses (*1)

       

Business segment information:

       

Wealth Management

     68,517        67,041       (2.2

Investment Management

     24,491        29,047       18.6  

Wholesale

     223,725        219,164       (2.0

Banking

     7,200        9,231       28.2  
  

 

 

    

 

 

   

 

 

 

Subtotal

     323,933        324,483       0.2  

Other

     27,578        38,550       39.8  
  

 

 

    

 

 

   

 

 

 

Non-interest expenses

     351,511        363,033       3.3  
  

 

 

    

 

 

   

 

 

 

Reconciliation items:

       

Unrealized gain (loss) on investments in equity securities held for operating purposes

     —         —        —   
  

 

 

    

 

 

   

 

 

 

Non-interest expenses

     351,511        363,033       3.3  
  

 

 

    

 

 

   

 

 

 

Income (loss) before income taxes

       

Business segment information:

       

Wealth Management

     41,199        38,755       (5.9

Investment Management

     23,179        21,527       (7.1)  

Wholesale

     21,121        41,908       98.4  

Banking

     4,032        3,614       (10.4
  

 

 

    

 

 

   

 

 

 

Subtotal

     89,531        105,804       18.2  

Other (*2)

     12,161        54,610       349.1  
  

 

 

    

 

 

   

 

 

 

Income (loss) before income taxes

     101,692        160,414       57.7  
  

 

 

    

 

 

   

 

 

 

Reconciliation items:

       

Unrealized gain (loss) on investments in equity

securities held for operating purposes

     1,239        (132     —   
  

 

 

    

 

 

   

 

 

 

Income (loss) before income taxes

     102,931        160,282       55.7  
  

 

 

    

 

 

   

 

 

 
 
(*1)

Includes primarily personnel expenses, occupancy, technology, and professional fees.

(*2)

Major components

Transactions between operating segments are recorded within segment results on commercial terms and conditions, and are eliminated in “Other.”

The following table presents the major components of income (loss) before income taxes in “Other.”

 

     Millions of yen     % Change  
   For the three months ended     (B-A)/(A)  
   June 30,
2024 (A)
    June 30,
2025 (B)
 

Net gain (loss) related to economic hedging transactions

     (2,853     1,067       —   

Realized gain (loss) on investments in equity securities held for operating purposes

     —        5       —   

Equity in earnings of affiliates

     14,800       12,321       (16.8)  

Corporate items

     5,519       (11,637     —   

Other

     (5,305     52,854       —   
  

 

 

   

 

 

   

 

 

 

Total

     12,161       54,610       349.1  
  

 

 

   

 

 

   

 

 

 
 

Note) Prior period amounts have been reclassified to conform to the current year presentation.

 

– 11 –


Table of Contents

(6) Significant Changes in Equity

Not applicable. For further details of the changes, please refer below.

 

     Millions of yen  
   For the three months ended
June 30, 2025
 

Common stock

  

Balance at beginning of year

     594,493  
  

 

 

 

Balance at end of period

     594,493  
  

 

 

 

Additional paid-in capital

  

Balance at beginning of year

     704,877  

Stock-based compensation awards

     (34,321

Changes in an affiliated company’s interests

     (15
  

 

 

 

Balance at end of period

     670,541  
  

 

 

 

Retained earnings

  

Balance at beginning of year

     1,867,379  

Net income attributable to NHI shareholders

     104,565  

Loss on disposal of treasury stock

     (8,835
  

 

 

 

Balance at end of period

     1,963,109  
  

 

 

 

Accumulated other comprehensive income (loss)

  

Cumulative translation adjustments

  

Balance at beginning of year

     407,977  

Net change during the period

     (40,038
  

 

 

 

Balance at end of period

     367,939  
  

 

 

 

Defined benefit pension plans

  

Balance at beginning of year

     (7,105

Pension liability adjustment

     (4,200
  

 

 

 

Balance at end of period

     (11,305
  

 

 

 

Non-trading debt securities

  

Balance at beginning of year

     (1,147

Net unrealized gain on non-trading debt securities

     387  
  

 

 

 

Balance at end of period

     (760
  

 

 

 

Own credit adjustments

  

Balance at beginning of year

     48,083  

Own credit adjustments

     (2,432
  

 

 

 

Balance at end of period

     45,651  
  

 

 

 

Balance at end of period

     401,525  
  

 

 

 

Common stock held in treasury

  

Balance at beginning of year

     (143,678

Repurchases of common stock

     (41,935

Sale of common stock

     0  

Common stock issued to employees

     31,959  
  

 

 

 

Balance at end of period

     (153,654
  

 

 

 

Total NHI shareholders’ equity

  
  

 

 

 

Balance at end of period

     3,476,014  
  

 

 

 

Noncontrolling interests

  

Balance at beginning of year

     110,120  

Net change during the period

     2,817  
  

 

 

 

Balance at end of period

     112,937  
  

 

 

 

Total equity

  
  

 

 

 

Balance at end of period

     3,588,951  
  

 

 

 

 

– 12 –


Table of Contents

(7) Note with respect to the Assumption as a Going Concern

Not applicable.

(8) Note with respect to Consolidated Statements of Cash Flows

The following table shows depreciation and amortization for the three months ended June 30, 2024 and 2025.

 

     Millions of yen  
   For the three months ended  
   June 30, 2024      June 30, 2025  

Depreciation and amortization

     16,112        15,407  

 

– 13 –


Table of Contents

3. Supplementary Information

(1) Consolidated Statements of Income – Quarterly Comparatives

 

    Millions of yen     % Change     Millions of yen  
    For the three months ended           For the year ended
March 31,
2025
 
    June 30,
2024
    September 30,
2024
    December 31,
2024
    March 31,
2025(A)
    June 30,
2025(B)
    (B-A)/(A)  

Revenue:

             

Commissions

    102,750       101,363       102,630       100,268       100,606       0.3       407,011  

Fees from investment banking

    41,251       53,335       64,375       53,273       38,357       (28.0     212,234  

Asset management and portfolio service fees

    90,333       93,848       97,209       96,806       92,855       (4.1     378,196  

Net gain on trading

    131,994       147,711       142,013       158,381       142,239       (10.2     580,099  

Gain on private equity and debt investments

    3,153       1,598       1,641       1,242       6,330       409.7       7,634  

Interest and dividends

    788,550       762,958       745,459       630,894       649,561       3.0       2,927,861  

Gain (loss) on investments in equity securities

    1,442       (2,554     1,610       (54     (377     —        444  

Other

    58,412       83,307       43,001       38,544       127,017       229.5       223,264  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

    1,217,885       1,241,566       1,197,938       1,079,354       1,156,588       7.2       4,736,743  

Interest expense

    763,443       758,239       695,957       626,619       633,273       1.1       2,844,258  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

    454,442       483,327       501,981       452,735       523,315       15.6       1,892,485  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-interest expenses:

             

Compensation and benefits

    184,510       184,671       190,888       172,321       186,310       8.1       732,390  

Commissions and floor brokerage

    43,629       45,325       43,645       44,853       44,778       (0.2     177,452  

Information processing and communications

    55,769       56,741       54,431       60,077       57,164       (4.8     227,018  

Occupancy and related depreciation

    17,635       16,810       17,885       17,836       15,965       (10.5     70,166  

Business development expenses

    6,572       5,981       6,807       7,695       6,992       (9.1     27,055  

Other

    43,396       40,789       50,046       52,209       51,824       (0.7     186,440  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total non-interest expenses

    351,511       350,317       363,702       354,991       363,033       2.3       1,420,521  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

    102,931       133,010       138,279       97,744       160,282       64.0       471,964  

Income tax expense

    31,498       35,304       34,137       23,770       52,808       122.2       124,709  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

    71,433       97,706       104,142       73,974       107,474       45.3       347,255  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Less: Net income (loss) attributable to noncontrolling interests

    2,495       (681     2,701       2,004       2,909       45.2       6,519  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to NHI shareholders

    68,938       98,387       101,441       71,970       104,565       45.3       340,736  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
    Yen     % Change     Yen  

Per share of common stock:

     

Basic-

             

Net income attributable to NHI shareholders per share

    23.33       33.30       34.32       24.35       35.19       44.5       115.30  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Diluted-

             

Net income attributable to NHI shareholders per share

    22.36       32.26       33.08       23.39       34.04       45.5       111.03  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

– 14 –


Table of Contents

(2) Business Segment Information – Quarterly Comparatives

The following table shows quarterly business segment information and reconciliation items to the consolidated statements of income.

 

     Millions of yen     % Change     Millions of yen  
     For the three months ended                      For the year ended  
     June 30,
2024
     September 30,
2024
    December 31,
2024
     March 31,
2025(A)
    June 30,
2025(B)
    (B-A)/(A)     March 31,
2025
 

Net revenue

                

Business segment information:

                

Wealth Management

     109,716        112,301       111,611        99,923       105,796       5.9       433,551  

Investment Management

     47,670        56,087       45,711        43,005       50,574       17.6       192,473  

Wholesale

     244,846        263,381       290,523        259,188       261,072       0.7       1,057,938  

Banking

     11,232        12,245       12,274        11,421       12,845       12.5       47,172  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Subtotal

     413,464        444,014       460,119        413,537       430,287       4.1       1,731,134  

Other

     39,739        42,545       41,244        39,372       93,160       136.6       162,900  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     453,203        486,559       501,363        452,909       523,447       15.6       1,894,034  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Reconciliation items:

                

Unrealized gain (loss) on investments in equity securities held for operating purposes

     1,239        (3,232     618        (174     (132     —        (1,549
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     454,442        483,327       501,981        452,735       523,315       15.6       1,892,485  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Non-interest expenses (*1)

                

Business segment information:

                

Wealth Management

     68,517        68,061       66,792        63,999       67,041       4.8       267,369  

Investment Management

     24,491        24,152       26,773        27,466       29,047       5.8       102,882  

Wholesale

     223,725        218,087       228,162        221,682       219,164       (1.1     891,656  

Banking

     7,200        7,632       7,612        8,371       9,231       10.3       30,815  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Subtotal

     323,933        317,932       329,339        321,518       324,483       0.9       1,292,722  

Other

     27,578        32,385       34,363        33,473       38,550       15.2       127,799  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Non-interest expenses

     351,511        350,317       363,702        354,991       363,033       2.3       1,420,521  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Reconciliation items:

                

Unrealized gain (loss) on investments in equity securities held for operating purposes

     —         —        —         —        —        —        —   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Non-interest expenses

     351,511        350,317       363,702        354,991       363,033       2.3       1,420,521  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

                

Business segment information:

                

Wealth Management

     41,199        44,240       44,819        35,924       38,755       7.9       166,182  

Investment Management

     23,179        31,935       18,938        15,539       21,527       38.5       89,591  

Wholesale

     21,121        45,294       62,361        37,506       41,908       11.7       166,282  

Banking

     4,032        4,613       4,662        3,050       3,614       18.5       16,357  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Subtotal

     89,531        126,082       130,780        92,019       105,804       15.0       438,412  

Other (*2)

     12,161        10,160       6,881        5,899       54,610       825.8       35,101  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

     101,692        136,242       137,661        97,918       160,414       63.8       473,513  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Reconciliation items:

                

Unrealized gain (loss) on investments in equity securities held for operating purposes

     1,239        (3,232     618        (174     (132           (1,549
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

     102,931        133,010       138,279        97,744       160,282       64.0       471,964  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 
 
(*1)

Includes primarily personnel expenses, occupancy, technology, and professional fees.

(*2)

Major components

Transactions between operating segments are recorded within segment results on commercial terms and conditions, and are eliminated in “Other.”

The following table presents the major components of income (loss) before income taxes in “Other.”

 

    Millions of yen     % Change     Millions of yen  
    For the three months ended                      For the year ended
March 31,
2025
 
    June 30,
2024
    September 30,
2024
    December 31,
2024
    March 31,
2025(A)
    June 30,
2025(B)
    (B-A)/(A)  

Net gain (loss) related to economic hedging transactions

    (2,853     1,826       (7,014     2,232       1,067       (52.2     (5,809

Realized gain (loss) on investments in equity securities
held for operating purposes

    —        496       645       334       5       (98.5     1,475  

Equity in earnings of affiliates

    14,800       11,551       15,200       9,670       12,321       27.4       51,221  

Corporate items

    5,519       (5,332     (954     (5,117     (11,637     —        (5,884

Other

    (5,305     1,619       (996     (1,220     52,854       —        (5,902
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

    12,161       10,160       6,881       5,899       54,610       825.8       35,101  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Note) Prior period amounts have been reclassified to conform to the current year presentation.

 

– 15 –


Table of Contents
(3)

Other

Quarterly financial information for Nomura Securities Co., Ltd. can be found at the following URL.

https://www.nomuraholdings.com/en/company/group/nsc/nsc/main/019/teaserItems2/0/linkList/0/link/2026_1q.pdf

 

– 16 –

FAQ

What event triggered Serina Therapeutics' July 29 2025 Form 8-K?

The company furnished a press release and presentation on the advancement of SER-270 and its appearance at the BTIG Virtual Biotechnology Conference.

Which SEC item was used in the Serina Therapeutics 8-K?

Item 7.01 – Regulation FD Disclosure.

What is SER-270 mentioned by Serina Therapeutics (SER)?

SER-270 is a POZ-conjugated VMAT2 inhibitor being developed for tardive dyskinesia.

Did the 8-K include financial results or guidance?

No. The filing contained no financial metrics, earnings data, or guidance.

Where can investors find the presentation materials?

The investor presentation is furnished as Exhibit 99.1 to the Form 8-K.

Is the furnished information considered filed for legal purposes?

No. Serina stated the information is furnished, not filed, and will not be incorporated into future filings unless specifically referenced.
Nomura Hldgs

NYSE:NMR

NMR Rankings

NMR Latest News

NMR Latest SEC Filings

NMR Stock Data

19.74B
2.95B
2.44%
0.02%
Capital Markets
Financial Services
Link
Japan
Tokyo